BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1435 related articles for article (PubMed ID: 22956068)

  • 21. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of re-excision for positive and close resection margins in patients treated with breast-conserving surgery.
    Biglia N; Ponzone R; Bounous VE; Mariani LL; Maggiorotto F; Benevelli C; Liberale V; Ottino MC; Sismondi P
    Breast; 2014 Dec; 23(6):870-5. PubMed ID: 25305040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
    Panoff JE; Hurley J; Takita C; Reis IM; Zhao W; Sujoy V; Gomez CR; Jorda M; Koniaris L; Wright JL
    Breast Cancer Res Treat; 2011 Aug; 128(3):899-906. PubMed ID: 21475999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.
    Jia H; Jia W; Yang Y; Li S; Feng H; Liu J; Rao N; Jin L; Wu J; Gu R; Zhu L; Chen K; Deng H; Zeng Y; Liu Q; Song E; Su F
    World J Surg Oncol; 2014 Sep; 12():289. PubMed ID: 25241216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence.
    Haffty BG; Hauser A; Choi DH; Parisot N; Rimm D; King B; Carter D
    Cancer; 2004 Jan; 100(2):252-63. PubMed ID: 14716758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reoperative Sentinel Lymph Node Biopsy is Feasible for Locally Recurrent Breast Cancer, But is it Worthwhile?
    Ugras S; Matsen C; Eaton A; Stempel M; Morrow M; Cody HS
    Ann Surg Oncol; 2016 Mar; 23(3):744-8. PubMed ID: 26644258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
    Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
    Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
    Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
    Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical research of local recurrence after breast-conserving therapy for breast cancer].
    Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
    Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(24):1851-4. PubMed ID: 21211266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast-conserving therapy in breast cancer patients--a 12-year experience.
    Mannell A
    S Afr J Surg; 2005 May; 43(2):28-30; discussion 30, 32. PubMed ID: 16035379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.